Comparative analysis of treatment response to PSMA radioligand therapy using Ga-68 PSMA-11 and F-18 DCFPyL PET imaging
- 1Department of Radiology and Biomedical Imaging, University of California, San Francisco , , ,
Abstract
Purpose: Multiple prostate-specific membrane antigen (PSMA) PET tracers are used for patient selection in radioligand therapy (RLT). This study compared treatment response to RLT across different PSMA tracers.
Methods: We retrospectively analyzed patients who underwent Lu-177 PSMA-617 RLT with baseline imaging using either Ga-68 PSMA-11 or F-18 DCFPyL PET. PET parameters were measured, including SUV mean , SUV max , and total tumor volume (TTV). Univariable and multivariable logistic regression analyses were performed to evaluate factors associated with PSA50 response, and Cox proportional hazards regression analyses were performed to evaluate factors associated with overall survival.
Results: Of 140 patients analyzed (Ga-68 PSMA-11: n=51; F-18 DCFPyL: n=89), SUV max and SUV mean did not differ significantly between groups; however, TTV was significantly higher in the Ga-68 PSMA-11 group (p=0.038). In multivariable analysis adjusted for age, baseline PSA, PET tracer type, SUVmean, and log-transformed TTV, PET tracer type was not significantly associated with PSA50 response (OR, 1.318; 95% CI, 0.585–2.970; p=0.505), whereas higher SUVmean was associated with greater odds of PSA50 response (OR, 1.285; 95% CI, 1.126–1.466; p<0.001). Overall survival did not differ significantly between tracer groups (HR, 0.760; 95% CI, 0.507–1.138; p=0.183), with median overall survival of 8.4 and 12.6 months. In multivariable analysis, PET tracer type was not significantly associated with overall survival (HR, 0.736; 95% CI, 0.475–1.139; p=0.168), whereas higher SUVmean was associated with a lower risk of death (HR, 0.886; 95% CI, 0.825–0.950; p<0.001) and higher log-transformed TTV was associated with a higher risk of death (HR, 1.415; 95% CI, 1.194–1.678; p<0.001).
Conclusion: PET tracer type was not significantly associated with PSA50 response or overall survival following RLT. Higher SUV mean was associated with greater odds of PSA50 response and a lower risk of death, whereas higher TTV was associated with overall survival.
Related
- Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.
- Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy
- Quantitative Molecular Breast Imaging for Early Prediction of Neoadjuvant Systemic Therapy Response in Locally Advanced Breast Cancer Patients
- Targeted radioligand therapy in oncology: clinical development across targets and platforms
- Comparative Effectiveness of Low-Dose Intra-Articular Ozone Therapy for Pain and Functional Outcomes in Patients with Knee Osteoarthritis: A Retrospective Cohort Study [Response to Letter].
BibTeX
@article{hong2026comparative,
title = {{Comparative analysis of treatment response to PSMA radioligand therapy using Ga-68 PSMA-11 and F-18 DCFPyL PET imaging}},
author = {Chae Moon Hong and Abuzar Moradi Tuchayi and Mansour Abtahi and Stellamaris Nwihim and Surekha Yadav and Robert R. Flavell and Thomas A. Hope},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1932583},
url = {https://europepmc.org/article/PMC/PMC13672183},
note = {CC BY},
}
RIS
TY - JOUR
TI - Comparative analysis of treatment response to PSMA radioligand therapy using Ga-68 PSMA-11 and F-18 DCFPyL PET imaging
AU - Chae Moon Hong
AU - Abuzar Moradi Tuchayi
AU - Mansour Abtahi
AU - Stellamaris Nwihim
AU - Surekha Yadav
AU - Robert R. Flavell
AU - Thomas A. Hope
PY - 2026
DA - 2026/10/02
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1932583
UR - https://europepmc.org/article/PMC/PMC13672183
AB - Purpose: Multiple prostate-specific membrane antigen (PSMA) PET tracers are used for patient selection in radioligand therapy (RLT). This study compared treatment response to RLT across different PSMA tracers. Methods: We retrospectively analyzed patients who underwent Lu-177 PSMA-617 RLT with baseline imaging using either Ga-68 PSMA-11 or F-18 DCFPyL PET. PET parameters were measured, including SUV mean , SUV max , and total tumor volume (TTV). Univariable and multivariable logistic regression analyses were performed to evaluate factors associated with PSA50 response, and Cox proportional hazards regression analyses were performed to evaluate factors associated with overall survival. Results: Of 140 patients analyzed (Ga-68 PSMA-11: n=51; F-18 DCFPyL: n=89), SUV max and SUV mean did not differ significantly between groups; however, TTV was significantly higher in the Ga-68 PSMA-11 group (p=0.038). In multivariable analysis adjusted for age, baseline PSA, PET tracer type, SUVmean, and log-transformed TTV, PET tracer type was not significantly associated with PSA50 response (OR, 1.318; 95% CI, 0.585–2.970; p=0.505), whereas higher SUVmean was associated with greater odds of PSA50 response (OR, 1.285; 95% CI, 1.126–1.466; p<0.001). Overall survival did not differ significantly between tracer groups (HR, 0.760; 95% CI, 0.507–1.138; p=0.183), with median overall survival of 8.4 and 12.6 months. In multivariable analysis, PET tracer type was not significantly associated with overall survival (HR, 0.736; 95% CI, 0.475–1.139; p=0.168), whereas higher SUVmean was associated with a lower risk of death (HR, 0.886; 95% CI, 0.825–0.950; p<0.001) and higher log-transformed TTV was associated with a higher risk of death (HR, 1.415; 95% CI, 1.194–1.678; p<0.001). Conclusion: PET tracer type was not significantly associated with PSA50 response or overall survival following RLT. Higher SUV mean was associated with greater odds of PSA50 response and a lower risk of death, whereas higher TTV was associated with overall survival.
SN - 2234-943X
ER -